Celgene, Google double down on Armo’s PhIII immuno-oncology drug with $67M round
Armo BioSciences has lined up a big $67 million C round to pay for the late-stage development of some of its immuno-oncology assets.
Launched and built with the help of some marquee investors like Celgene, Kleiner Perkins, GV (Google) and OrbiMed, Armo has now attracted some major league Chinese VCs to its pipeline work. Qiming Venture Partners led the round with help from new investors Decheng Capital, Sequoia Capital, Quan Capital and RTW Investments. All the original backers came back in for the C round.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.